Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 10/20 | 0.60 |
| ▸ | PPARA | Q07869 | 4/20 | 0.48 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GPR27 | Q9NS67 | 1/20 | 0.44 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.43 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.42 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7036839 | 0.91 | PPARG (0.56) | PPARGPPARAKMT2AMEN1GPR27 | |
| Lithium Ion SCHEMBL7040200 | 0.91 | PPARG (0.70) | PPARGPPARAKMT2AMEN1GPR27 | |
| SCHEMBL7036036 | 0.82 | PPARG (0.81) | PPARGPPARAKMT2ASERPINE1HPGD | |
| SCHEMBL7035737 | 0.81 | PPARG (0.83) | PPARGPPARAKMT2ASERPINE1HPGD | |
| SCHEMBL7040287 | 0.81 | PPARG (0.70) | PPARGPPARAKMT2ASERPINE1HPGD | |
| SCHEMBL7037688 | 0.80 | PPARG (0.63) | PPARGPPARASERPINE1HPGD | |
| SCHEMBL7041258 | 0.80 | PPARG (0.71) | PPARGPPARAKMT2ASERPINE1HPGD | |
| SCHEMBL7035613 | 0.79 | PPARG (0.64) | PPARGPPARAGRIK1KMT2AMEN1 | |
| SCHEMBL7040599 | 0.79 | PPARG (0.61) | PPARGPPARASERPINE1 | |
| SCHEMBL7040746 | 0.79 | PPARG (0.64) | PPARGPPARASERPINE1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073862-A1 | Compounds | BIOVITRUM AB (SE) | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073862-A1 | Compounds | PPARG, PPARA, PPARD | PPARG 1/4885PPARA 2/4885GRIK1 970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.